XTLbio announces appointment of Non-Executive Director



Rehovot, 12 January 2004 - XTL Biopharmaceuticals Ltd. (LSE:XTL) is pleased to
announce the appointment of Peter Stalker, III, as a non-Executive director
with immediate effect.

Peter Stalker was formerly a Managing Director at E. M. Warburg Pincus and Co.
Inc., one of the largest private equity and venture capital firms in the world.
During his tenure from 1984 to 1998, he was responsible for overseeing
venture-banking investments in the biotechnology, pharmaceutical and specialty
chemical industries. In this capacity, Mr. Stalker worked closely with the
managements of over 30 portfolio companies, overseeing both private and public
financings for more than a dozen biotechnology companies.

Currently Mr. Stalker serves as a director of several privately held companies
including OpenSource Asia and Biogenex. In addition, he is actively engaged on
the board of a number of national and local not-for-profit organizations
including The National Alliance for Hispanic Health, where he is treasurer and
member of the executive committee, and the Connecticut chapter of The Nature
Conservancy.

Mr. Stalker graduated magna cum laude from Princeton University in 1982.

Commenting on the appointment, Dr Geoffrey Vernon, Chairman of XTLbio, said:

"We are delighted to welcome Peter Stalker as a non-Executive Director of
XTLbio. Peter's vast experience in the biotech industry with particular
emphasis on financing and the public markets in the United States is an
important addition to our Board."

There are no disclosures required under paragraph 6.F.2. (b)-(g).


XTL CONTACTS
Dr. Martin Becker
President and CEO
+972-8-930-4440
 

Financial Dynamics
David Yates, Sarah MacLeod
+44 (0) 20 7831 3113

Notes to Editors

XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. XTLbio's HepeX(tm) product line - now in clinical trials
- has the potential to introduce revolutionary therapies for viral hepatitis,
including prevention of re-infection in transplanted livers, the Company's
primary focus, and a longer-term cocktail approach in treating chronic illness.
XTLbio believes its primary competitive advantage lies in its patented Trimera(tm)
technology, which enables the development of fully human monoclonal antibodies
and models of human disease for pre-clinical drug validation. Established in
1993, XTLbio became a public company in 2000 with shares traded on the London
Stock Exchange under the symbol XTL. 



END